Analysis of Fcγ receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B by Morgan, A.W. et al.
Available online http://arthritis-research.com/content/8/1/R5Open AccessVol 8 No 1Research article
Analysis of Fcγ receptor haplotypes in rheumatoid arthritis: 
FCGR3A remains a major susceptibility gene at this locus, with an 
additional contribution from FCGR3B
Ann W Morgan1,2, Jennifer H Barrett1, Bridget Griffiths2,5, Deepak Subramanian1, Jim I Robinson1, 
Viki H Keyte1, Manir Ali1, Elizabeth A Jones3, Robert W Old3, Frederique Ponchel1, 
Arthur W Boylston1, R Deva Situnayake4, Alexander F Markham1, Paul Emery2 and John D Isaacs2,5
1Institute of Molecular Medicine, Epidemiology and Cancer Research, University of Leeds, St James's University Hospital, Beckett Street, Leeds, LS9 
7TF, UK
2Academic Unit of Musculoskeletal Disease, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK
3Department of Biological Sciences, University of Warwick, Coventry, CV4 7AL, UK
4City Hospital, Birmingham, Sandwell and West Birmingham Hospitals, NHS Trust, City Hospital Site, Dudley Road, Birmingham, B18 7QH, UK
5School of Clinical Medical Sciences (Musculoskeletal Research Group) University of Newcastle-Upon-Tyne, Framligton Place, Newcastle-Upon-
Tyne, NE2 4HH, UK
Corresponding author: Ann W Morgan, a.w.morgan@leeds.ac.uk
Received: 28 Jul 2005 Revisions requested: 13 Sep 2005 Revisions received: 19 Sep 2005 Accepted: 10 Oct 2005 Published: 10 Nov 2005
Arthritis Research & Therapy 2006, 8:R5 (doi:10.1186/ar1847)
This article is online at: http://arthritis-research.com/content/8/1/R5
© 2005 Morgan et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
The Fcγ receptors play important roles in the initiation and
regulation of many immunological and inflammatory processes,
and genetic variants (FCGR) have been associated with
numerous autoimmune and infectious diseases. The data in
rheumatoid arthritis (RA) are conflicting and we previously
demonstrated an association between FCGR3A and RA. In
view of the close molecular proximity with FCGR2A, FCGR2B
and FCGR3B, additional polymorphisms within these genes
and FCGR haplotypes were examined to refine the extent of
association with RA. Biallelic polymorphisms in FCGR2A,
FCGR2B and FCGR3B were examined for association with RA
in two well characterized UK Caucasian and North Indian/
Pakistani cohorts, in which FCGR3A genotyping had previously
been undertaken. Haplotype frequencies and linkage
disequilibrium were estimated across the FCGR locus and a
model-free analysis was performed to determine association
with RA. This was followed by regression analysis, allowing for
phase uncertainty, to identify the particular haplotype(s) that
influences disease risk. Our results reveal that FCGR2A,
FCGR2B and FCGR3B were not associated with RA. The
haplotype with the strongest association with RA susceptibility
was the FCGR3A–FCGR3B 158V-NA2 haplotype (odds ratio
3.18, 95% confidence interval 1.13–8.92 [P = 0.03] for
homozygotes compared with all genotypes). The association
was stronger in the presence of nodules (odds ratio 5.03, 95%
confidence interval 1.44–17.56; P = 0.01). This haplotype was
also more common in North Indian/Pakistani RA patients than in
control individuals, but not significantly so. Logistic regression
analyses suggested that FCGR3A remained the most
significant gene at this locus. The increased association with an
FCGR3A–FCGR3B haplotype suggests that other
polymorphic variants within FCGR3A or FCGR3B, or in linkage
disequilibrium with this haplotype, may additionally contribute to
disease pathogenesis.
Introduction
Rheumatoid arthritis (RA) is a heterogeneous disease charac-
terised by a chronic, fluctuating, peripheral, symmetrical and
erosive polyarthritis. It has been reported throughout the
world, with a prevalence rate of approximately 1% in most pop-
ulations [1]. Persistent synovial inflammation leads to progres-
sive joint destruction, which in turn produces deformity and
significant disability. In addition, RA is a systemic disease andPage 1 of 9
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secondary Sjögren's syndrome, episcleritis and scleritis, inter-
stitial lung disease, pericardial involvement, systemic vasculitis
and Felty's syndrome. These extra-articular manifestations of
RA appear to be rare in the absence of rheumatoid factor (RF),
and IgG RF titres correlate with articular disease severity and
with the extra-articular manifestations of RA [2]. In addition to
RF, many other IgG autoantibodies are found in RA, most nota-
bly anti-cyclic citrullinated peptide [3] and anti-type II collagen
antibodies [4].
The Fcγ receptors (FcγRs), which bind these IgG autoantibod-
ies and IgG-containing immune complexes, have been shown
to play important roles in the initiation and regulation of many
immunological and inflammatory processes. In humans, there
are three classes of FcγRs (I-III) encoded by eight genes,
which produce at least 15 different membrane-bound and sol-
uble isoforms that vary in their cellular distribution and affinity
for different IgG isotypes. This molecular and expression diver-
sity restricts specific biological properties to certain cell types.
Activating (FcγRIIa, FcγRIIIa and FcγRIIIb) and inhibitory
(FcγRIIb) FcγRs are frequently coexpressed on the same cell,
thus providing a means for regulating signalling thresholds
[5,6]. Furthermore, the absolute level of receptor expression is
modulated by proinflammatory and anti-inflammatory cytokines
[7]. Activating functions include uptake and clearance of
immune complexes (complement dependent and independent
mechanisms), activation of phagocytes (trigger the oxidative
burst, cytotoxic granule and cytokine release), antigen presen-
tation and antibody-dependent cellular cytotoxicity [6]. Con-
versely, FcγRIIb contains an inhibitory motif in the cytoplasmic
tail and abrogates cellular activation. FcγRIIb may also play a
role in maintaining peripheral B cell tolerance and prevention
of autoimmunity [8]. Single and multiple FcγR knockout mouse
models have demonstrated that the balance between activat-
ing and inhibitory FcγRs influences the development of both
immune complex-mediated and collagen-induced arthritis
[9,10].
Polymorphic variants that increase the expression or affinity of
these IgG receptors or that enhance their ability to bind spe-
cific IgG isotypes may therefore play an important role in deter-
mining the severity and persistence of inflammation to IgG
(auto)antibodies and immune complexes in RA. Our previous
studies have supported an association between FCGR3A and
RA. The higher affinity FCGR3A-158V allele was associated
with an increased susceptibility to RA, with homozygotes dem-
onstrating a 1.5-fold to twofold increased risk for RA and a
twofold to fourfold increase in nodules [11,12]. In keeping with
several other RA susceptibility genes, this association has not
been replicated in all populations [13-18]. There was a trend
toward an increased frequency of the FCGR3A-158V allele in
Norwegian and Dutch RA patients [16,18], with a skewing
toward the FCGR3A-158F allele in Spanish, Japanese and
Indian populations [13-15,17]. Many reasons for the lack of
reproducibility of association studies have been proposed and
include differences in the design, power and accuracy of gen-
otyping strategies in the various studies. The apparently con-
flicting results may also be a consequence of a genuine
difference in the genetic and environmental susceptibility fac-
tors according to the precise ethnic group or disease pheno-
type under investigation. Nonreplication may thus indicate a
real biological difference between populations. Alternatively, if
FCGR3A is in linkage disequilibrium with the true RA-suscep-
tibility locus then, because the extent of linkage disequilibrium
varies between different populations, the association may only
exist in certain populations and contribute to nonreplication of
findings [12,19].
FCGR3A lies in a 200 kilobase FCGR gene cluster on 1q22-
23 in close molecular proximity to FCGR2A, FCGR3B and
FCGR2B [20]. Functional single nucleotide polymorphisms
(SNPs) in the latter genes have been investigated as genetic
susceptibility and severity factors in multiple infectious and
autoimmune diseases [5,6]. We therefore undertook addi-
tional genotyping in our original RA cohorts and examined
SNPs in FCGR2A, FCGR2B and FCGR3B; examined the
extent of linkage disequilibrium at this locus; and analyzed
FCGR haplotypes for association with disease in order to
investigate the possibility that there are other RA susceptibility
variants at this locus. We demonstrate an increased associa-
tion with a FCGR3A–FCGR3B haplotype, which suggests
that other polymorphic variants within FCGR3A or FCGR3B,
or in linkage disequilibrium with this haplotype may additionally
contribute to disease pathogenesis.
Materials and methods
Rheumatoid arthritis patients and control individuals
This was an allelic association study conducted to examine
FCGR2A, FCGR2B and FCGR3B, and FCGR haplotypes in
two well characterized RA cohorts in which an association
between FCGR3A and RA was previously identified [11]. The
recruitment and clinical characteristics of these two RA and
control populations, resident in Birmingham, UK have previ-
ously been described [11,21]. They comprise 294 UK Cauca-
sian individuals (150 RA patients and 144 healthy control
individuals) and 256 North Indian/Pakistani individuals (126
RA patients and 130 healthy control individuals). Ethical
approval was obtained from the respective local research eth-
ics committees.
Elucidation of the FCGR gene order
Computational assemblies of 1q23 at the National Center for
BioInformatics [22], Ensembl [23] and Oak Ridge National
Laboratory [24] websites resulted in several variations in
FCGR gene order, thus necessitating the construction of an
electronic contig. Genomic exon sequences of the class II
(FCGR2A, FCGR2B and FCGR2C) and class III (FCGR3A
and FCGR3B) genes were aligned to enable identification of
homologous regions and specific nucleotides thatPage 2 of 9
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containing the class II and III FCGR genes was identified by
performing BLAST (basic local alignment search tool)
sequence homology searches at the National Centre for Bio-
Informatics [22] using five 30-base-pair homologous regions
from each receptor class. The bacterial artificial chromosome
(BAC) sequence fragments were primarily aligned by the iden-
tification of complete gene sequences and overlapping
sequence data from neighbouring BACs, and the final assem-
bly was facilitated by utilizing published restriction enzyme
maps of this locus [20,25].
FCGR2B sequence analysis
At the time when this study was performed, several putative
polymorphic variants of FCGR2B had been identified in a
cDNA library [26], but these had not been substantiated by
sequencing genomic DNA. These included a 2-base-pair dele-
tion at positions 208–210 at the start of exon 3, a G→A sub-
stitution at position 685 in exon 4, a functionally significant
T→G substitution at position 855 in exon 6 [27] and a G→A
substitution at position 1206 in the 3'-untranslated region
(UTR). Two potential polymorphic sites (rs844 and rs1043) in
STS accession G06355 (UniSTS:73835) were also identified
from the reference SNP database, which corresponded to the
3'-UTR of FCGR2B.
The genomic sequence alignments of the class II FCGR
genes (FCGR2A, FCGR2C and FCGR2B), generated as
described above, were used to design FCGR2B-specific
PCRs to facilitate direct sequencing of exons 3 and 6 and the
3'-UTR. The primer sequences and annealing temperatures of
the different PCR reactions are shown in Table 1. Briefly, 20
µl PCRs were performed using 100 ng DNA, 200 nmol/l of
each primer, 40 µmol/l each of 4 dNTPs, 1.5 mmol/l MgCl2
and 0.5 units of Taq DNA polymerase (Promega, Southamp-
ton, UK). The PCR reaction was performed in 30 individuals
using a Techne Genius PCR machine (Techne [Cambridge]
Ltd, Ducksford, Cambridge, UK) and the PCR conditions were
95°C for 5 minutes followed by 38 cycles of 95°C for 30 s,
annealing temperature for 60 s and 72°C for 60 s, with a final
extension step of 72°C for 10 minutes. Fluorescent automated
cycle sequencing of the PCR products was performed using
a dRhodamine terminator reaction kit (PE Biosystems, War-
rington, UK). Electrophoresis was performed on polyacryla-
mide gels using the ABI PRISM® 377 DNA Sequencer
(Applied Biosystems, Foster City, CA, USA) and the sequence
analyzed utilizing ABI PRISM® 377 sequencing software.
FCGR genotyping
FCGR2A
The FCGR2A-131H/R functional polymorphism has a G→A
substitution at nucleotide 519, which results in a switch from
arginine (R) to histidine (H) at amino acid position 131 in the
immunoglobulin-binding domain [28]. Genotyping was per-
formed using a nested amplification refractory mutation sys-
tem (ARMS) PCR approach. A 322 bp PCR product was
amplified (30 cycles) using a combination of previously pub-
lished FCGR2A-specific primer sequences (PCR1 and 4INM)
[28]. A 1:500 dilution served as a template for two separate
nested ARMS PCRs that utilized 400 nmol/l of the published
Table 1
Primer pairs used to amplify specific FCGR sequencing templates
Gene Forward 
primer
Sequence Reverse 
primer
Sequence Annealing 
temperature 
(°C)
Sequencing primers
FCGR2A IIA-SF dGGAGAAACCATCATGCTGAG IIA-SR dCAATTTTGCTGCTATGGGC 52
FCGR2B (E3) IIB-E3SF dGGCATCTCAAGCTCC IIB-E3SR dAGAGTCACAGAGTCCTCC 58
FCGR2B (E6) IIB-E6SF dCCCATCCAACCCTGG IIB-E6SR dGGCAGATTCCTCAGCAAATCA 56
FCGR2B (3'UTR) IIB-UTRSF dTGGGGAGGACAGGGAGAT IIB-UTRSR dATCACTTTTAATGTGCTGGTAGAGG 63
Genotyping primers
FCGR2A PCR1 dGGAGAAACCATCATGCTGAG 4INM dCAATTTTGCTGCTATGGGC 52
IIA-R dAATCCCAGAAATTCTCCCG IIA-H dAATCCCAGAAATTCTCCCA
FCGR3B-NA1 IIIB-NA1F dCAGTGGTTTCACAATGTGAA IIIB-NA1R dATGGACTTCTAGCTGCACCG 54
IIIB-NA1PR dGTCTCTTTCTGCTTGGTGATGG IIIB-NA1PR dTTTTCCCCTCTAAACTGGG
FCGR3B-NA2 IIIB-NA2F dCTCAATGGTACAGCGTGCTT IIIB-NA2R dCTGTACTCTCCACTGTCGTT 62
IIIB-NA2PR dCTGGCTTGCTGATGAAGATAC IIIB-NA2PR dGTAACGCTTNGGCACCACC
FCGR2B IIB-UTRSF dTGGGGAGGACAGGGAGAT IIB-UTRGR dCAGAAGGTGCAGTCGGC 50
The mutation inserted into the FCGR2B reverse nested primer (IIB-UTRGR) is shown in italics. This introduced an allele-specific HaeIII restriction 
site (GGCC) in the presence of the G but not the A allele.Page 3 of 9
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positive control and a 246 bp product indicated the presence
of either the FCGR2A-131H or R allele, according to the
ARMS primer used. Specific amplification of FCGR2A, rather
than the highly homologous FCGR2B and FCGR2C, and the
+519 SNP, was confirmed in 40 individuals by direct
sequencing.
FCGR2B
The FCGR2B-1206G/A polymorphism was genotyped using
a nested RFLP assay. The 330 bp FCGR2B-specific
sequencing PCR product (see above) was diluted 1:200 and
served as a template for a second PCR that used IIB-UTRSF
and a mutated reverse primer (IIB-UTRGR), which introduced
an allele-specific HaeIII restriction site. The resultant PCR
product was incubated at 37°C for 1 hour with 6U HaeIII
(Promega) and the products visualized using a 3.5% agarose
gel.
FCGR3A
Additional DNA samples that had not yielded reliable results
on direct sequencing [11] were genotyped using our single-
stranded conformational polymorphism assay [12] and were
included in the haplotype analysis.
FCGR3B
The functional neutrophil antigen (NA)1 and NA2 alleles of
FCGR3B were genotyped using minor modifications to a pre-
viously published ARMS PCR assay, which included both
allele-specific primers and a distinct internal control [30]. The
NA1 assay included the two ARMS primers IIIB-NA1F and
IIIB-NA1R, and an internal control (fragment of FCGR3A and
FCGR3B) was amplified by IIIB-NA1PF and IIIB-NA1PR. The
NA2 assay similarly included the IIIB-NA2F and IIIB-NA2R
ARMS primers and internal control primers IIIB-NA2PR and
IIIB-NA2PR from the gene MCSD1.
Statistical analyses
Statistical analyses were performed using the Stata statistical
software (Stata Statistical Software, release 8.0; Stata Corpo-
ration, College Station, TX, USA) unless otherwise stated.
Hardy–Weinberg equilibrium was investigated in each control
population using a goodness-of-fit test to check whether the
observed pattern of genotype frequencies was consistent with
expectations. Allele and genotype frequencies were compared
using 2 × 2 and 3 × 2 contingency tables, respectively. Nod-
ules are only rarely present during the early stages of RA and
their absence does not indicate that they may not develop in
the future. The control population was therefore felt to be the
most appropriate reference group for analysis of the subgroup
with nodular RA [31].
Haplotype frequencies were estimated pair-wise across the
FCGR locus using the Estimating Haplotypes PLUS
(EHPLUS) program [32]. A pair-wise measure of linkage dise-
quilibrium (D') was also calculated for each pair of FCGR
genes. Association with disease was tested for by comparing
the haplotype frequencies estimated from cases and controls
separately with estimates based on the combined sample,
using a likelihood ratio test. A permutation procedure imple-
mented in the EHPLUS program was used to assess statisti-
cal significance based on 1,000 permutations [32].
Table 2
Genotype frequencies in UK Caucasian and North Indian/Pakistani rheumatoid arthritis patients and healthy controls
Gene Genotype UK Caucasian North Indian/Pakistani
Control (n = 129) RA (n = 147) P Nodular RA (n = 37) P Control (n = 128) RA (n = 123) P
FCGR2A-131 RR 39 (0.31) 40 (0.28) 0.81 7 (0.19) 0.36 25 (0.19) 30 (0.25) 0.15
RH 59 (0.47) 72 (0.49) 21 (0.58) 66 (0.52) 48 (0.39)
HH 28 (0.22) 34 (0.23) 8 (0.22) 37 (0.29) 44 (0.36)
FCGR3A-158 FF 68 (0.48) 59 (0.39) 0.15 12 (0.31) 0.02 63 (0.49) 48 (0.38) 0.21
FV 61 (0.43) 69 (0.46) 17 (0.45) 57 (0.44) 66 (0.52)
VV 12 (0.09) 22 (0.15) 9 (0.24) 9 (0.07) 12 (0.10)
FCGR3B-NA 22 48 (0.37) 55 (0.38) 0.13 16 (0.43) 0.28 49 (0.39) 47 (0.39) 0.25
21 72 (0.56) 71 (0.48) 16 (0.43) 45 (0.35) 53 (0.43)
11 9 (0.07) 21 (0.14) 5 (0.14) 33 (0.26) 22 (0.18)
FCGR2B-1206 GG 56 (0.48) 67 (0.46) 0.96 16 (0.43) 0.19 61 (0.48) 58 (0.47) 0.98
GA 50 (0.42) 63 (0.43) 13 (0.35) 54 (0.43) 54 (0.44)
AA 12 (0.10) 16 (0.11) 8 (0.22) 11 (0.09) 11 (0.09)
Values are expressed as number (%). RA, rheumatoid arthritis.Page 4 of 9
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example, which variants are inherited from the same parent) is
unknown. Association of FCGR3A–FCGR3B haplotypes with
RA was investigated further using the haplotype trend regres-
sion (HTR) approach proposed by Zaykin and coworkers [33]
for dealing with uncertain phase. In this method logistic regres-
sion can be used to predict disease status from an individual's
haplotypes; where these are not known with certainty, all hap-
lotypes consistent with the genotypes are included as predic-
tors, weighted by their probabilities. This approach estimates
the effect on risk for each haplotype, assuming that each of the
individual's two haplotypes can have an independent effect.
Stepwise regression analyses were also used to investigate
the joint effect of the FCGR genes [34].
Results
Chromosomal order of the FCGR genes
The FCGR genes were located on three BAC clones: RP11-
474I16 (EMBL: AL359541) contained FCGR2B; RP11-
25I17 (EMBL: AC021370) contained FCGR2B, FCGR2C,
FCGR3A and FCGR3B; and the final clone RP11-5K23
(EMBL: AC013307) contained FCGR3A and FCGR2A. The
complete genomic sequence of each FCGR (with the excep-
tion of the 5' part of FCGR2C) was identified on these BAC
clones. Alignment of the sequence fragments demonstrated
the FCGR gene order from centromere to telomere at chromo-
some 1q23 as FCGR2A, FCGR3A, FCGR2C, FCGR3B,
FCGR2B. Similar work is in agreement with this gene order
[35].
FCGR2B sequencing
The rs844 G→A substitution was confirmed and was identical
to that described previously at position 1206 [26], and this
SNP was therefore designated FCGR2B-1206G/A. No fur-
ther polymorphisms were identified in exons 3 or 6 or the 3'-
UTR of FCGR2B in 30 control individuals and RA patients.
Association of FCGR2A, FCGR3B and FCGR2B with 
rheumatoid arthritis
Genotyping was complete on 274 Caucasian individuals (147
cases and 127 controls) and 249 North Indian/Pakistani indi-
viduals (122 cases and 127 controls). FCGR2A, FCGR3A
and FCGR2B were in Hardy–Weinberg equilibrium in both
control groups. FCGR3B was not in Hardy–Weinberg equilib-
rium (for the UK Caucasian group: P = 0.01; for the North
Indian/Pakistani group: P = 0.002). We subsequently
sequenced more than 200 individuals with 100% agreement
with our genotyping assays to exclude genotyping error as an
explanation.
No significant differences in the allele or genotype distribu-
tions were seen for FCGR2A, FCGR3B, or FCGR2B in either
RA group compared with controls (Table 2). The results for
FCGR3A in our expanded UK Caucasian cohort were consist-
ent with our previous findings [11]. Homozygosity for the
FCGR3A-158V allele demonstrated a trend toward and asso-
ciation with RA (odds ratio [OR] 2.1, 95% confidence interval
[CI] 1.0–4.7; P = 0.06) and significant association with nodu-
lar RA (OR 4.3, 95% CI 1.5–12.3; P = 0.005).
Linkage disequilibrium at the FCGR genetic locus
There was evidence of weak linkage disequilibrium (D' = 0.30,
P = 0.01) between FCGR2A and FCGR3A in the UK Cauca-
sian but not the North Indian/Pakistani control populations.
Highly significant linkage disequilibrium was seen between
FCGR3B and FCGR2B in both populations (UK Caucasian:
D' = -0.68, P = 0.0001; North Indian/Pakistani:D' = -0.52, P
= 0.0001). The negative D' values indicate linkage disequilib-
rium between the common allele of one gene and the rare
allele of the second gene. No significant linkage disequilibrium
was detected between FCGR3A and FCGR3B in either eth-
nic group, although D' = 0.40 in the UK Caucasian group
(Table 3).
Association of FCGR haplotypes with rheumatoid 
arthritis
The distributions of two locus FCGR haplotypes were com-
pared between the RA cohorts and their control populations,
with a difference approaching statistical significance for
FCGR3A–FCGR3B (Table 4). Compared with the control fre-
quency of 24%, the FCGR3A–FCGR3B 158V-NA2 haplo-
type was found at increased frequency in UK Caucasian RA
patients (31%) and even higher frequency in those with nodu-
lar RA (37%).
From the HTR analysis of FCGR3A–FCGR3B haplotypes, the
158V-NA2 haplotype was found to have a significant effect on
the risk for RA in UK Caucasians (OR 1.77, 95% CI 1.09–
2.87; P = 0.02), taking the most common haplotype (158F-
NA2) as baseline (Table 5). The effect was stronger in the
small subgroup of UK Caucasian individuals with nodules (OR
2.51, 95% CI 1.15–5.49; P = 0.02).
These are estimates of the effect of each haplotype, assuming
that each of the individual's two haplotypes has an independ-
ent effect on risk with a combined multiplicative effect. The
effect of the 158V-NA2 haplotype was found to be largely con-
fined to those with two copies of this haplotype (data not
Table 3
Pair-wise linkage disequilibrium measures (D') calculated from 
the control groups in the two populations
FCGR2A FCGR3A FCGR3B
FCGR3A 0.30 (0.18)
FCGR3B 0.05 (0.23) -0.40 (-0.21)
FCGR2B -0.10 (0.05) 0.00 (-0.34) -0.68 (-0.52)
Shown are D' measures for the UK Caucasian (and North Indian/
Pakistani) populations. Values with a magnitude of 0.3 and higher 
highlighted in bold.Page 5 of 9
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homozygosity for this haplotype was compared in the control
population (frequency 4%) with the total RA population (11%),
giving an OR of 3.18 (95% CI 1.13–8.92; P = 0.03) when
comparing homozygotes with all others. Again, the effect of
homozygosity was stronger in those with nodular RA (fre-
quency 16%; OR 5.03, 95% CI 1.44–17.56; P = 0.01).
For the North Indian/Pakistani cohort the same haplotype was
found to be at increased frequency in RA patients compared
with controls (OR 1.52, 95% CI 0.82–2.80, from the HTR
analysis) but the difference was not statistically significant (P
= 0.19; Table 5). Homozygosity for this haplotype was seen in
approximately 4% of the RA and 1.5% of the control
population.
Stepwise logistic regression analyses of FCGR3A and 
FCGR3B in the Caucasian group
Considering each locus separately, FCGR3A is associated
with RA in Caucasians [11] but FCGR3B is not (Table 2).
However comparing the model containing both genotypes
with the model containing FCGR3A only, there is an improved
fit with inclusion of FCGR3B (χ2 = 6.27, 2 degrees of free-
dom, from likelihood ratio test; P = 0.04). When the cohort
with nodules was examined, the inclusion of FCGR3B did not
significantly improve the model (P = 0.22).
Contribution of FCGR haplotypes and shared epitope 
alleles in rheumatoid arthritis susceptibility
One advantage of the HTR framework for analysis of haplo-
types is that other factors can be included in the model. The
analysis was repeated including the RA-associated 'shared
epitope' (SE) alleles (positive or negative) in the models. As
expected, the SE itself was still highly predictive of RA in these
models (OR 3.16, 95% CI 1.75–5.71 in UK Caucasians; OR
3.94, 95% CI 2.17–7.18 in the North Indian/Pakistani group).
There was evidence of a multiplicative joint effect between SE
and the FCGR haplotypes, consistent with both of these two
genetic factors contributing to the risk for disease. Thus, the
risk for RA in SE-positive UK Caucasian individuals
homozygous for the FCGR3A–FCGR3B 158V-NA2 haplo-
type is increased tenfold compared with those with other
FCGR3 genotypes who are SE negative.
Discussion
Haplotype analyses have started to assume an increased
importance in genetic studies of human disease because they
can be more informative in their ability to identify unique chro-
mosomal segments that are likely to harbour disease predis-
posing genes. They may also provide additional evidence for
the presence of further unidentified polymorphic variants that
are the true disease-susceptibility variants [36]. We have dem-
onstrated an increased level of association between
FCGR3A–FCGR3B haplotypes and RA compared with
FCGR3A alone. The effects were stronger in the subset of RA
patients with nodules. The two-locus haplotype showing the
Table 4
Estimated pairwise haplotype frequencies in rheumatoid arthritis patients and healthy controls
Genes Haplotype UK Caucasian North Indian/Pakistani
Control RA Pa Nodular RA P Control RA P
FCGR2A-FCGR3A 131R-158F 0.43 0.41 0.25 0.32 0.13 0.34 0.30 0.46
131R-158V 0.11 0.11 0.16 0.11 0.15
131H-158F 0.27 0.22 0.22 0.36 0.34
131H-158V 0.19 0.26 0.30 0.19 0.21
FCGR3A-FCGR3B 158F-NA2 0.42 0.31 0.08 0.27 0.07 0.38 0.36 0.33
158F-NA1 0.28 0.32 0.27 0.34 0.29
158V-NA2 0.24 0.31 0.37 0.19 0.25
158V-NA1 0.06 0.06 0.09 0.10 0.11
FCGR3B-FCGR2B NA2-1206G 0.36 0.34 0.77 0.35 0.41 0.33 0.33 0.45
NA2-1206A 0.29 0.27 0.30 0.24 0.28
NA1-1206G 0.31 0.33 0.26 0.37 0.37
NA1-1206A 0.04 0.06 0.09 0.06 0.03
Pairwise haplotypes produced from four biallelic markers (FCGR2A-131H/R, FCGR3A-158F/V, FCGR3B-NA2/1 and FCGR2B-1206G/A) 
denoted in the order they occur at the FCGR locus. Thus, 131R-158F indicates a haplotype containing FCGR2A-131R and FCGR3A-158F 
alleles. aEmpirical P values obtained from a heterogeneity test statistic incorporated in the PM program after 1,000 permutations. RA, rheumatoid 
arthritis.Page 6 of 9
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Available online http://arthritis-research.com/content/8/1/R5strongest association with RA susceptibility in each group was
the FCGR3A–FCGR3B 158V-NA2 haplotype. UK Caucasian
individuals who were homozygous for this haplotype were esti-
mated to be at threefold risk for disease compared with all oth-
ers (OR 3.18, 95% CI 1.13–8.92; P = 0.03), and this analysis
does not depend on inference of uncertain phase because
individuals that are homozygous for a haplotype are unambig-
uously identified by their genotype. The relative importance of
the FCGR3A-158V and FCGR3B-NA2 polymorphic variants
were assessed further using stepwise regression analyses
[34]. These analyses showed that, although only FCGR3A has
been shown to be associated with RA [11], the model includ-
ing both loci provided an improved fit for RA susceptibility, but
not necessarily so for the development of nodules. In the North
Indian/Pakistani population there was a 6% increase in the
FCGR3A–FCGR3B 158V-NA2 haplotype, but this failed to
reach statistical significance.
Several methods have been proposed for the analysis of such
data in the absence of family data and the consequent pres-
ence of phase uncertainty. The HTR method we have chosen
to use has various advantages. The method uses all the data,
including that from individuals with uncertain phase. Because
the data are analyzed in a regression framework, the usual
regression diagnostics are available, other factors can be
included in the model and tests for interaction can be per-
formed. A potential disadvantage of the method is that weights
used in the regression analysis are based on estimated haplo-
type frequencies, and the uncertainty inherent in the estimates
is ignored in the model. This leads to an anti-conservative test
and could lead to false-positive results. However, Stram and
coworkers [37] evaluated the method in comparison with
other more sophisticated approaches and found it to perform
well in most situations.
Haplotype frequencies were estimated using the expectation-
maximization algorithm, which has been shown to perform
well, even in the presence of some departure from Hardy–
Weinberg equilibrium [38]. Errors due to sampling are gener-
ally of much greater concern than inaccuracies due to the esti-
mation process.
We acknowledge that none of our results are highly statisti-
cally significant when a consideration is made for multiple
tests. However, the consistent pattern of results, taken in con-
junction with prior findings in relation to these genes and their
known biological functions in humans and mice, gives addi-
tional credence to them. Replication of these findings in other
populations will ultimately be required.
The FcγRs play important roles in the initiation and propaga-
tion of many different immunological and inflammatory proc-
esses. Consequently, they may act as susceptibility factors for
RA through a variety of mechanisms. FCGR3A was the most
significant gene in this study, and we have previously dis-
cussed the role that this receptor may play in RA pathogenesis
[11,12]. In humans, FcγRIIIa is expressed on natural killer cells,
macrophages, γδ T cells, a subset of monocytes and cultured
mast cells [5,6]. Higher levels of FcγRII and FcγRIII expression
have been demonstrated in synovial biopsy specimens from
RA patients compared with control individuals [39]. Similarly,
an increase in the expression level and proportion of circulat-
ing FcγRIIIa-positive monocytes has been observed in RA and
may correlate with disease activity [40,41]. In addition, in vitro
derived macrophages from RA patients expressed more
FcγRII and FcγRIIIa, and released higher levels of tumour
necrosis factor-α and matrix degrading enzymes in response
to heat-aggregated IgG [39] compared with controls. These
findings are supportive of our own work whereby the higher
affinity genetic variant of FCGR3A may sensitize FcγR-bearing
cells to IgG-containing immune complexes. FcγRIIIa may also
play an important role delivering (auto)antigens, and activation
and maturation signals to dendritic cells [42]. This may provide
an explanation for the over tenfold increased risk for RA in SE-
positive Caucasian individuals homozygous for the FCGR3A–
FCGR3B 158V-NA2 haplotype, which has been a consistent
finding by a number of groups [11-13,15,18].
FcγRIIIb is selectively expressed on neutrophils and eosi-
nophils, and has a low affinity for IgG. It is linked to the mem-
brane by a glycosylphosphatidylinositol anchor and does not
appear to associate with the known transmembrane adapter
molecules [5,6]. However, FcγRIIIb appears to interact with
FcγRIIa in the phagocytosis of immune complexes and subse-
Table 5
Haplotype trend regression in rheumatoid arthritis patients and healthy controls for FCGR3A-FCGR3B haplotypes
Haplotype UK Caucasian North Indian/Pakistani
RA P Nodular RA P RA P
158F-NA2 1 (baseline) - 1 (baseline) - 1 (baseline) -
158F-NA1 1.62 (0.99–2.66) 0.05 1.58 (0.67–3.70) 0.29 0.96 (0.60–1.54) 0.85
158V-NA2 1.77 (1.09–2.87) 0.02 2.51 (1.15–5.49) 0.02 1.52 (0.82–2.80) 0.19
158V-NA1 1.44 (0.61–3.40) 0.41 2.00 (0.63–6.39) 0.24 1.22 (0.63–2.37) 0.55
Values are expressed as odds ratio (95% confidence interval). RA, rheumatoid arthritis.Page 7 of 9
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through the ITAM (immunoreceptor tyrosine-based activation
motif) of FcγRIIa [43,44]. FCGR3B has two common polymor-
phic forms, namely NA1 and NA2, which differ in five nucle-
otides that produce four amino acid differences. This alters the
number of glycosylation sites, and neutrophils from individuals
homozygous for the FCGR3B-NA2 allele have been found
consistently to exhibit lower levels of phagocytosis than
FCGR3B-NA1 homozygotes [45]. This polymorphism has
important biological consequences, especially in the develop-
ment of blood transfusion reactions, autoimmune neutropenias
and the severity of renal disease in systemic vasculitis [6,46].
Individuals with duplications and deletions of FCGR3B have
been reported [30,47], with the estimated frequency of the
FCGR3B deletion being 0.001–0.08 in various Caucasian
populations [48]. Standard genotyping assays, as performed
in the present study, do not allow a calculation of the gene
copy number. This may provide an explanation for a failure of
our control populations to conform to Hardy–Weinberg equi-
librium and the previously reported non-Mendelian segrega-
tion in some Caucasian families [49].
FcγRIIb plays a crucial role in the regulation of antibody pro-
duction and susceptibility to several spontaneous and induced
murine autoimmune diseases [50-52]. We found no evidence
of an association between FCGR2B- or FCGR2B-containing
haplotypes and RA in our cohorts, unlike previous observa-
tions in a Japanese cohort in which an alternative SNP in
FCGR2B was investigated [15].
Conclusion
There is good data that FcγRs may be critical modulators of
inflammation within the synovium and that subtle changes in
either expression or structure of these receptors may influence
both the susceptibility to RA and the development of nodules.
The analyses performed in this study have strengthened our
original observation that the FCGR genetic locus is associ-
ated with RA, particularly in a UK Caucasian population with
nodular disease. Our haplotype data, together with the step-
wise regression analysis, suggest that additional polymorphic
variants within FCGR3A or in linkage disequilibrium with the
FCGR3A–FCGR3B 158V-NA2 haplotype may contribute to
RA pathogenesis.
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